Business
Maiden Preliminary Results for FY15
Maiden Preliminary Results for FY15.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 0702B Shield Therapeutics PLC 14 June 2016 \n\n \n \n \n \nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\n \nMaiden Preliminary Results for the Year Ended 31 December 2015\n \nLondon, UK, 14 June 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical Company focused on secondary care, today announces its maiden preliminary Group results for the year ended 31 December 2015.\n \nHighlights (including post period end)\nOperational \n· Pan-European Marketing Authorisation Approval of Feraccru for the treatment of Iron Deficiency Anaemia (\"IDA\") in Inflammatory Bowel Disease (\"IBD\") received in February 2016\n· Subsequent launch of Feraccru utilising the Company's own in-house commercial team commenced in the UK during May 2016\n· Feraccru to be priced in the UK at £47.60 per pack (£1.70 per day equivalent) as agreed with the Department of Health\n· Two additional Phase 3 studies of Feraccru have commenced to support future expansion of the market opportunity for Feraccru\n· Successful completion of Phase 2b pivotal trial for PT20 in dialysis-dependent Chronic Kidney Disease (\"CKD\") patients and drug substance manufacturing for second pivotal study\n· Significant investment in Shield's operational team with headcount now at 45, increased from 14 at the year end\n \nFinancial1\n· Successful completion of an Initial Public Offering (IPO) on AIM of the London Stock Exchange in February 2016 raising £32.5m (gross) and further potential gross proceeds of £17.5m, subject to the full exercise of Warrants\n· Net loss for FY2015 of £24.5m on IFRS basis; EPS loss of £0.57 per share\n· Adjusted net loss for FY2015, excluding the impact of the pre-IPO capital and equity structure, of £5.3m, loss per share of £0.13\n· Year end net cash of £0.7m; net cash as at 31st May 2016 of £28.8m\n \n____________________________________\n1 Note: the Company’s FY2015 results reflect the structure of the group pre-IPO and are pre-acquisition of Phosphate Therapeutics Limited which completed post year end.\n ...